Role of PET/CT in Metastatic Female Breast Cancer
Mohamed Hassan Ibrahim Hassona;
Abstract
SUMMARY
C
ancer breast is the most frequently diagnosed cancer and the leading cause of cancer death among females, accounting for 23% of the total cancer cases and 14% of the cancer deaths.
The vast majority of metastatic cancer breast is incurable and hence the main treatment goal is palliation, with the aim of maintaining and improving quality of life and possibly prolonging survival. Therapy is not generally considered curative.
In early breast cancer, routine staging evaluations (Baseline systemic imaging staging) are directed at loco-regional disease such as chest computed tomography (CT), abdominal ultrasound or CT scan and bone scan should be considered for patients with clinically positive axillary nodes, large tumors (e.g. ≥5 cm) or clinical signs, symptoms or laboratory values suggesting the presence of metastases.
18F-FDG PET /CT is recommended as an option for patients with either recurrent or stage IV disease in earlier breast guidelines and recent PET-specific guidelines.
Dual imaging methods combining functional and anatomical information such as fluorodeoxyglucose positron emission tomography (FDG-PET)/CT may be useful when conventional methods are inconclusive.
C
ancer breast is the most frequently diagnosed cancer and the leading cause of cancer death among females, accounting for 23% of the total cancer cases and 14% of the cancer deaths.
The vast majority of metastatic cancer breast is incurable and hence the main treatment goal is palliation, with the aim of maintaining and improving quality of life and possibly prolonging survival. Therapy is not generally considered curative.
In early breast cancer, routine staging evaluations (Baseline systemic imaging staging) are directed at loco-regional disease such as chest computed tomography (CT), abdominal ultrasound or CT scan and bone scan should be considered for patients with clinically positive axillary nodes, large tumors (e.g. ≥5 cm) or clinical signs, symptoms or laboratory values suggesting the presence of metastases.
18F-FDG PET /CT is recommended as an option for patients with either recurrent or stage IV disease in earlier breast guidelines and recent PET-specific guidelines.
Dual imaging methods combining functional and anatomical information such as fluorodeoxyglucose positron emission tomography (FDG-PET)/CT may be useful when conventional methods are inconclusive.
Other data
| Title | Role of PET/CT in Metastatic Female Breast Cancer | Other Titles | دور التصوير بالاشعة المقطعية مع المسح البوزيتروني للجسم كله في المرضي الذين يعانون من سرطان الثدي المنتشر | Authors | Mohamed Hassan Ibrahim Hassona | Issue Date | 2017 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.